NASDAQ:ZNTL
Zentalis Pharmaceuticals, Inc.
- Stock
Last Close
11.96
17/05 20:00
Market Cap
897.31M
Beta: 1.83
Volume Today
493.17K
Avg: 602.77K
PE Ratio
−2.91
PFCF: −3.94
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
net income | -23.43M - | -46.38M 97.93% | -118.55M 155.61% | -166.09M 40.11% | -237.11M 42.76% | -292.19M 23.23% | |
depreciation and amortization | 51K - | 111K 117.65% | 160K 44.14% | 544K 240% | 1.43M 162.13% | 1.39M 2.59% | |
deferred income tax | 2.37M - | 7.78M 228.79% | 17K 99.78% | -2.46M 14,582.35% | -769K 68.77% | -853K 10.92% | |
stock based compensation | 308K - | 617K 100.32% | 23.15M 3,651.38% | 35.74M 54.40% | 46.84M 31.07% | 54.82M 17.04% | |
change in working capital | -1.18M - | 6.51M 652.38% | 7.84M 20.55% | 16.56M 111.08% | 13.25M 19.96% | 5.86M 55.75% | |
accounts receivables | -254K - | 777K 405.91% | -277K 135.65% | 413K 249.10% | |||
inventory | -1.86M - | -1.51M 18.97% | -5.52M 265.98% | 881K 115.96% | |||
accounts payables | 977K - | 7.12M 629.07% | 14.31M 100.86% | 13.92M 2.73% | 15.53M 11.58% | 10.92M 29.68% | |
other working capital | -40K - | 115K 387.50% | -667K 680% | 1.35M 301.95% | -2.27M 268.89% | -5.05M 122.20% | |
other non cash items | -2.37M - | -7.78M 228.79% | 556K 107.15% | -38.38M 7,002.16% | 12.61M 132.87% | 23.15M 83.52% | |
net cash provided by operating activities | -24.25M - | -39.14M 61.41% | -86.83M 121.81% | -154.09M 77.48% | -163.75M 6.27% | -207.82M 26.91% | |
investments in property plant and equipment | -227K - | -352K 55.07% | -758K 115.34% | -6.11M 705.67% | -2.55M 58.28% | -583K 77.12% | |
acquisitions net | 18.42M - | -14.32M 177.72% | 111.63K 100.78% | ||||
purchases of investments | -400.98M - | -363.51M 9.35% | -533.16M 46.67% | -549.18M 3.00% | |||
sales maturities of investments | 116.91M - | 365.82M 212.91% | 421.53M 15.23% | 505.31M 19.87% | |||
other investing activites | -18.42M - | -111.63K - | |||||
net cash used for investing activites | -227K - | -352K 55.07% | -284.83M 80,818.18% | -18.11M 93.64% | -114.18M 530.31% | -44.46M 61.06% | |
debt repayment | |||||||
common stock issued | 16K - | 81.83M 511,337.50% | 327.79M 300.57% | 179.67M 45.19% | 261.04M 45.29% | 237.30M 9.09% | |
common stock repurchased | -1.15K - | ||||||
dividends paid | |||||||
other financing activites | 9.46M - | -46K 100.49% | 32.65M 71,082.61% | -1.14M 103.51% | |||
net cash used provided by financing activities | 9.47M - | 81.83M 763.91% | 360.44M 340.47% | 178.52M 50.47% | 261.04M 46.23% | 237.30M 9.09% | |
effect of forex changes on cash | -54K - | ||||||
net change in cash | -15.01M - | 42.34M 382.12% | -11.22M 126.50% | 6.31M 156.28% | -16.89M 367.51% | -15.03M 11.00% | |
cash at beginning of period | 40.16M - | 25.15M 37.37% | 67.49M 168.30% | 56.27M 16.62% | 62.58M 11.22% | 43.07M 31.18% | |
cash at end of period | 25.15M - | 67.49M 168.30% | 56.27M 16.62% | 62.58M 11.22% | 45.70M 26.98% | 28.04M 38.64% | |
operating cash flow | -24.25M - | -39.14M 61.41% | -86.83M 121.81% | -154.09M 77.48% | -163.75M 6.27% | -207.82M 26.91% | |
capital expenditure | -227K - | -352K 55.07% | -758K 115.34% | -6.11M 705.67% | -2.55M 58.28% | -583K 77.12% | |
free cash flow | -24.48M - | -39.49M 61.35% | -87.58M 121.76% | -160.20M 82.91% | -166.30M 3.81% | -208.41M 25.32% |
All numbers in USD (except ratios and percentages)